Trial Details
COMPLETEDBasic Information
| Clinical ID | c1811 |
|---|---|
| Identifier | NCT04018599 |
| Trial Title | Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Rheumatoid Arthritis|Polyarticular Juvenile Idiopathic Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Crohn Disease|Ulcerative Colitis|Plaque Psoriasis|Pediatric Plaque Psoriasis|Pediatric Crohns Disease|Hidradenitis Suppurativa|Non-infectious Uveitis |
| Interventions | DRUG: 40 mg MSB11022|DRUG: 40 mg MSB11022 |
Participant Information
| Sponsor | Fresenius Kabi SwissBioSim GmbH |
|---|---|
| City | Lenexa |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE1 |
Time Information
| Start Date | 2019-07-15 |
|---|---|
| Primary Completion Date | 2020-03-17 |
| Completion Date | 2020-03-17 |